Navigation Links
Multiple Sclerosis drug, Tysabri banned due to neurological disorders

Tysabri, which is used in the treatment of Multiple Sclerosis (MS), has been withdrawn from market after the two patients taking the drug complained of neurological disorders. The relationship between the drug and // Progressive Multifocal Leukoencephalopathy (PML) is being researched by the scientists. If the drug is deemed to pose a significant risk, it could be a serious setback for the entire class of drugs, which work by blocking passage of immune cells in to the brain.

“Other cell migration inhibitors in development will have to be carefully tested, says Howard Weiner, director of the partners MS center at Brigham and Women’s Hospital. Several companies are developing drugs that use the same compounds to treat Crohn disease, rheumatoid arthritis and asthma. The US FDA has halted a phase 2 trial of a GlaxoSmithKline drug that targets the same protein, alpha-4 integrin, as Tysabri. Australian biotech Antisense Therapuetics stopped Phase 2 trial in March for similar MS drugs, which the company had also planned to develop as an asthma treatment. The FDA in November 2004 granted Tysabri fast track approval, after initial phase 3 results attacks by as much as 66%. Tysabri was expected to be a major blockbuster for its manufacturer Biogen Idec, but the company suspended sales of Tysabri in February, after learning of the two PML cases, one of which was fatal. The company also halted trials of the drug for rheumatoid arthritis and Crohn disease.

There has never previously been a documented case of PML in MS patients, even though these patients have been treated with many types of immunosuppresants. Both patients diagnosed with PML had taken Tysabri with Avonex, another MS drug, for two years n clinical trials.

Source: Nature Medicie
'"/>




Page: 1

Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina ... of New York was founded by James M. Maisel, MD and has been providing tertiary ... has always followed a legacy of surpassing expectations amongst her peers. Growing up in ...
(Date:12/5/2016)... ... December 05, 2016 , ... Routine ... measurements are consistently correct. However, regular performance testing is often neglected because ... a solution: SmartCal™ . This innovative test substance offers a fast ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released ... improves the reproducibility and accuracy of placing precordial electrodes with little cognitive effort ... the last 60 years, studies have shown that single electrode misplacement is one ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... transitions and many more tools allowing FCPX editors to create professional looking video ... Studios. , Perfect Harmony contains a beautifully designed 3D environment for placing ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior ... the Dallas area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ ... Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- PharmaBoardroom today releases its new 70 page Switzerland ... , ... investors, policymakers, and stakeholders crucial insight into Switzerland ; ... home to some of the world,s most important international health institutions as ... and with a number one ranking globally in terms of ease of ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... , Dec. 2, 2016  Former Attorney General of ... , a partner at the law firm of Kahn Swick ... investigation into Lannett Company, Inc. (NYSE: LCI ). ... published an article titled "U.S. Charges in Generic-Drug Probe to ... by the Justice Department, begun about two years ago, now ...
Breaking Medicine Technology: